Implementation of guideline-recommended therapies in heart failure with reduced ejection fraction according to heart failure duration: An analysis of 55 581 patients from the Swedish Heart Failure (SwedeHF) Registry
Most patients received RASI and beta-blockers in the first months following HFrEF diagnosis. Use of ARNI, MRA and SGLT2i was limited, both in the early and later time periods. Our findings suggest that strategies to improve guideline-directed use of HFrEF therapies remain urgently needed.
Authors
- Gianluigi Savarese (ORCID: https://orcid.org/0000-0001-7732-0887)
- Cecilia M. Linde (ORCID: https://orcid.org/0000-0002-9039-6023)
- Angiza Shahim (ORCID: https://orcid.org/0000-0002-4574-149X)
- Ulf Dahlström (ORCID: https://orcid.org/0000-0001-6353-8041)
- Camilla Hage (ORCID: https://orcid.org/0000-0002-4142-2416)
- Lars H. Lund
Institutions
- Linköping University (SE)
- Karolinska University Hospital (SE)
- Karolinska Institutet (SE)
Publication Details
- Journal
- European Journal of Heart Failure
- Published
- 2025-01-09
- DOI
- https://doi.org/10.1002/ejhf.3565
- Citations
- 13
- Primary Topic
- Heart Failure Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 18.05